Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Post-statin approaches to hyperlipidaemia.

P Duriez1, J C Fruchart

  • 1Université de Lille et Département d'Athérosclérose, U325 INSERM, InstitutPasteur, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cedex, France.

Expert Opinion on Investigational Drugs
|July 5, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overview. PPAR and cardiovascular risk.

Journal of cardiovascular risk·2001
Same author

PPARS in inflammation, atherosclerosis and thrombosis.

Journal of cardiovascular risk·2001
Same author

[New concepts on the mechanism of action of fibrates and therapeutic prospectives in atherosclerosis].

Bulletin de l'Academie nationale de medecine·2001
Same author

Polymorphisms in the insulin response element of APOC-III gene promoter influence the correlation between insulin and triglycerides or triglyceride-rich lipoproteins in humans.

International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity·2001
Same author

Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta.

The Journal of biological chemistry·2001
Same author

Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.

The Journal of clinical investigation·2001
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

New drugs target lipoprotein metabolism beyond statins, addressing hypertriglyceridaemia and other conditions. Research explores novel molecules like ACAT inhibitors, fibrates, RXR activators, and MTP inhibitors for improved lipid management.

Area of Science:

  • Lipid metabolism and cardiovascular disease research.
  • Pharmacological interventions for dyslipoproteinaemia.

Background:

  • Statins effectively treat hypercholesterolaemia but not other atherogenic lipoprotein abnormalities.
  • Conditions like hypertriglyceridaemia, mixed hyperlipidaemia, and low HDL-cholesterol remain challenging.
  • Atherosclerosis development is linked to various lipoprotein disturbances.

Purpose of the Study:

  • To review emerging therapeutic strategies for dyslipoproteinaemia beyond statins.
  • To highlight novel drug targets and molecules under development.
  • To discuss the potential of new pharmacological agents in managing atherogenic lipid profiles.

Main Methods:

  • Review of current pharmaceutical research and development in lipid-lowering agents.

Related Experiment Videos

  • Analysis of preclinical and early clinical data for novel drug candidates.
  • Exploration of new molecular targets including PPARalpha, ACAT, MTP, and RXR.

    • Main Results:

    • Several novel molecules targeting ACAT, PPARalpha, and RXR show promise in preclinical models.
    • BW-USC-148, a ureido fibrate analogue, demonstrates significant hypocholesterolaemic activity via PPARalpha activation.
    • Targretin (LGD1069) effectively reduces triglyceridaemia and increases HDL levels in animal models.

    Conclusions:

    • Advancements in understanding dyslipoproteinaemia drive the development of potent normolipidaemic drugs.
    • Novel therapeutic strategies are expanding treatment options for complex lipid disorders.
    • Future treatments may include ACAT inhibitors, MTP inhibitors, RXR activators, and potentially Vitamin E and gene therapy.